@article{oai:nagasaki-u.repo.nii.ac.jp:00027403,
 author = {Urata, Shuzo and Omotuyi, Olaposi Idowu and Izumisawa, Ayako and Ishikawa, Takeshi and Mizuta, Satoshi and Sakurai, Yasuteru and Mizutani, Tatsuaki and Ueda, Hiroshi and Tanaka, Yoshimasa and Yasuda, Jiro},
 journal = {Antiviral Research},
 month = {Feb},
 note = {The central role of Ebola virus (EBOV) VP40 in nascent virion assembly and budding from infected host cells makes it an important therapeutic target. The mechanism of dimerization, following oligomerization of VP40 leading to the production of virus-like particles (VLP) has never been investigated for the development of therapeutic candidates against Ebola disease. Molecular dynamics-based computational screening targeted VP40 dimer with 40,000,000 compounds selected 374 compounds. A novel in vitro screening assay selected two compounds, NUSU#1 and NUSU#2. Conventional VLP assays consistently showed that both compounds inhibited EBOV VP40-mediated VLP production. Intriguingly, NUSU#1 inhibited the VP40-mediated VLP pro-duction in other ebolavirus species and the Marburg virus, but did not inhibit Lassa virus Z-mediated VLP production. These results strongly suggested that the selected compounds are potential lead drug candidates against Filovirus disease via disruption of VP40-mediated particle production., Antiviral Research, 199, art. no. 105267; 2022},
 title = {Identification of novel chemical compounds targeting filovirus VP40-mediated particle production},
 volume = {199},
 year = {2022}
}